Lovastatin causes diminished PSA secretion by inhibiting AR expression and function in LNCaP prostate cancer cells

Urology

Volumn 77, Issue 6, 2011, Pages 1508.e1-1508.e7

  Yang, Lin ^a,b,c   Egger, Martina ^a,b,c   Plattner, Raffael ^a,b,c   Klocker, Helmut ^a,b,c   Eder, Iris E ^a,b,c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b PEKING UNIVERSITY   (China)

^c NATIONAL UROLOGICAL CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CASPASE 3; LUCIFERASE; MEVINOLIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; SMALL INTERFERING RNA; THYMIDINE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOASSAY; LYMPH NODE CARCINOMA; LYMPHATIC SYSTEM TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 79957892969     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.12.074     Document Type: Article

References (30)

1. Ferdinand KC. Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular disease. Curr Med Res Opin. 2005;21:1091-1097. (Pubitemid 41032700)
2. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med. 2000;160:2363-2368.
3. Hamilton RJ, Aronson WJ, Terris MK, et al. Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database. J Urol. 2008;179:1785-1789; [Discussion:1789-1790].
4. Hamilton RJ, Goldberg KC, Platz EA, et al. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst. 2008;100:1511-1518.
5. Krane LS, Kaul SA, Stricker HJ, et al. Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. J Urol. 2010;183:118-124.
6. Loeb S, Kan D, Helfand BT, et al. Is statin use associated with prostate cancer aggressiveness? BJU Int. 2010;105:1222-1225.
7. Mener DJ, Cambio A, Stoddard DG, et al. The impact of HMGCoA reductase therapy on serum PSA. Prostate. 2010;70:608-615.
8. Lieberman R. Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer. Am J Ther. 2004;11:501-506.
9. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276-308. (Pubitemid 38501396)
10. Cinar B, Mukhopadhyay NK, Meng G, et al. Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains. J Biol Chem. 2007;282:29584-29593. (Pubitemid 350043392)
11. Hager MH, Solomon KR, Freeman MR. The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care. 2006;9:379-385.
12. Freeman MR, Cinar B, Lu ML. Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab. 2005;16:273-279.
13. Zhuang L, Kim J, Adam RM, et al. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005;115:959-968. (Pubitemid 40489400)
14. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-430.
15. Link KA, Burd CJ, Williams E, et al. BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF. Mol Cell Biol. 2005;25:2200-2215. (Pubitemid 40354619)
16. Desiniotis A, Schäfer G, Klocker H, et al. Enhanced anti-proliferative and pro-apoptotic effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP dependent protein kinase A. Int J Cancer. 2010;126(3):775-789.
17. Haag P, Bektic J, Bartsch G, et al. Androgen receptor downregulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol. 2005;96:251-258. (Pubitemid 41080506)
18. Reddy GP, Barrack ER, Dou QP, et al. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. J Cell Biochem. 2006;98:1408-1423. (Pubitemid 44141847)
19. Cyrus-David MS, Weinberg A, Thompson T, et al. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report. J Urol. 2005;173:1923-1925. (Pubitemid 40675212)
20. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 1996;2:483-491.
21. Wong WW, Dimitroulakos J, Minden MD, et al. HMG-CoA Reductase Inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002;16:508-519. (Pubitemid 34460459)
22. Sun M, Yang L, Feldman RI, et al. Activation of phosphatidylinositol 3-kinase/Akt pathway by androgen through interaction of p85alpha, androgen receptor, and Src. J Biol Chem. 2003;278:42992-43000. (Pubitemid 37345912)
23. Zhu Q, Youn H, Tang J, et al. Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene. 2008;27:4569-4579.
24. Oh HY, Leem J, Yoon SJ, et al. Lipid raft cholesterol and genistein inhibit the cell viability of prostate cancer cells via the partial contribution of EGFR-Akt/p70S6k pathway and down-regulation of androgen receptor. Biochem Biophys Res Commun. 2010;393:319-324.
25. Shibata MA, Kavanaugh C, Shibata E, et al. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis. 2003;24:453-459. (Pubitemid 36432640)
26. Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 2008;17:88-94. (Pubitemid 351196277)
27. Murtola TJ, Pennanen P, Syvala H, et al. Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations. Prostate. 2009;69:1017-1023.
28. Snoek R, Cheng H, Margiotti K, et al. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. Clin Cancer Res. 2009;15:39-47.
29. Park C, Lee I, Kang WK. Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis. 2001;22:1727-1731. (Pubitemid 32952154)
30. Sivaprasad U, Abbas T, Dutta A. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther. 2006;5:2310-2316. (Pubitemid 44530468)